Abstract
Current medications for alcohol use disorder do not target brain noradrenergic pathways. Theoretical and preclinical evidence suggests that noradrenergic circuits may be involved in alcohol reinforcement and relapse. After a positive pilot study, the authors tested the α-1 adrenergic receptor antagonist prazosin to treat alcohol use disorder in a larger sample. Ninety-two participants with alcohol use disorder but without posttraumatic stress disorder were randomly assigned to receive prazosin or placebo in a 12-week double-blind study. Medication was titrated to a target dosing schedule of 4 mg in the morning, 4 mg in the afternoon, and 8 mg at bedtime by the end of week 2. The behavioral platform was medical management. Participants provided daily data on alcohol consumption. Generalized linear mixed-effects models were used to examine the impact of prazosin compared with placebo on number of drinks per week, number of drinking days per week, and number of heavy drinking days per week. Eighty participants completed the titration period and were included in the primary analyses. There was a significant interaction between condition and week for both number of drinks and number of heavy drinking days, such that the rate of drin...Continue Reading
Citations
Oct 16, 2018·Alcoholism, Clinical and Experimental Research·Shaunna L ClarkEdwin van den Oord
Nov 20, 2019·Addiction·Matt VassarMichael Bibens
Feb 11, 2020·Annual Review of Clinical Psychology·Gaylen E FronkJohn J Curtin
Jun 5, 2020·Journal of Dual Diagnosis·Yvette Z SzaboLaura Zambrano-Vazquez
May 26, 2020·Alcoholism, Clinical and Experimental Research·Verica MilivojevicHelen C Fox
Jun 24, 2020·Alcoholism, Clinical and Experimental Research·Saul JaimeRueben A Gonzales
May 21, 2019·Current Opinion in Psychiatry·Mehdi FarokhniaLorenzo Leggio
Jun 15, 2019·Psychopharmacology·Jesse T KayeJohn J Curtin
Feb 23, 2020·Frontiers in Behavioral Neuroscience·Cristina E María-Ríos, Jonathan D Morrow
Jul 23, 2020·Der Nervenarzt·Michael Soyka, Susanne Rösner
Sep 23, 2020·Addiction·Paul VanderkamClaire Lafay-Chebassier
Oct 8, 2020·Nature Reviews. Neuroscience·Marco VenniroYavin Shaham
Nov 20, 2020·The American Journal of Psychiatry·Rajita SinhaHelen C Fox
Feb 23, 2021·Expert Opinion on Pharmacotherapy·Kirsten C MorleyPaul Haber
Jul 15, 2021·Pharmacological Reviews·Ida FredrikssonYavin Shaham
Aug 4, 2021·Alcoholism, Clinical and Experimental Research·A Benjamin SrivastavaNasir H Naqvi
Dec 3, 2021·Addiction Biology·Rajita SinhaGretchen Hermes